What's in HK inno.N Corporation's pipeline?

HK inno.N Corporation has 70 drugs in our index: 5 marketed, 0 filed, 10 in Phase 3, 4 in Phase 2, 51 in Phase 1.

Which companies overlap with HK inno.N Corporation's portfolio?

Top competitors by shared drug class: Eli Lilly and Company, GlaxoSmithKline, Merck Sharp & Dohme LLC, Daewoong Pharmaceutical Co. LTD., Ahn-Gook Pharmaceuticals Co.,Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hk-inno-n-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

HK inno.N Corporation — Portfolio Competitive Intelligence Brief

HK inno.N Corporation pipeline: 5 marketed, 0 filed, 10 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 10 Phase 3 4 Phase 2 51 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Candesartan cilexetil/Amlodipine besylate	Candesartan cilexetil/Amlodipine besylate	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel	Cardiovascular
Lansoprazole/Amoxicillin/Clarithromycin	Lansoprazole/Amoxicillin/Clarithromycin	marketed	Proton pump inhibitor + antibiotic combination	H+ ATPase (lansoprazole); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)	Gastroenterology / Infectious Disease
Xarlin (Levocetirizine)	Xarlin (Levocetirizine)	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 receptor	Allergy/Immunology
A-prexa	A-prexa	marketed	Atypical antipsychotic	D2 receptor	Psychiatry
Lansoprazole 15 mg	Lansoprazole 15 mg	marketed
RAPAE01	RAPAE01	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
RPN301	RPN301	phase 3	GLP-1 receptor agonist	GLP-1R	Endocrinology / Diabetes
RCN301	RCN301	phase 3			Immunology
Tegoprazan/Amoxicillin/Clarithromycin	Tegoprazan/Amoxicillin/Clarithromycin	phase 3	Proton pump inhibitor (tegoprazan) + antibiotic combination (amoxicillin/clarithromycin)	H+/K+-ATPase (tegoprazan); bacterial cell wall and protein synthesis (amoxicillin/clarithromycin)	Gastroenterology
Amlodipine 5mg, Candesartan cilexetil 16mg	Amlodipine 5mg, Candesartan cilexetil 16mg	phase 3
CJ-30001/CJ-30002	CJ-30001/CJ-30002	phase 3	Dual GLP-1/GCG receptor agonist	GLP-1 receptor, Glucagon receptor	Endocrinology/Diabetes
IN-C006 Peri inj.	IN-C006 Peri inj.	phase 3	Immune checkpoint inhibitor	PD-1	Oncology

Therapeutic area mix

Diabetes · 2
Oncology · 2
Gastroenterology · 2
Endocrinology/Diabetes · 1
Gastroenterology / Infectious Disease · 1
Immunology · 1
Infectious Disease · 1
Allergy/Immunology · 1
Psychiatry · 1
Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Eli Lilly and Company · 4 shared drug classes
GlaxoSmithKline · 4 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes
Daewoong Pharmaceutical Co. LTD. · 3 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 3 shared drug classes
Assistance Publique - Hôpitaux de Paris · 3 shared drug classes
AstraZeneca · 3 shared drug classes
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for HK inno.N Corporation:

Cite this brief

Drug Landscape (2026). HK inno.N Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hk-inno-n-corporation. Accessed 2026-05-16.